Published: 2019-05-29

Correlation of serum parameters with disease severity, exacerbations and hospitalizations in patients with Non-cystic fibrosis bronchiectasis

John Sonia Kallarakal, Fathahudeen A., K. G. R. Mallan, Manjula V. D.


Background: The factors essential to define the severity and the prognosis of subjects with NCFB have not been sufficiently assessed. A prospective observational study was conducted to assess the serum parameters, their correlation with BSI (bronchiectasis severity index) and FACED (FEV1% predicted, age, chronic colonization by pseudomonas aeruginosa, extension by radiological assessment and dyspnoea) score in assessing disease severity and respiratory hospitalizations in patients with NCFB.

Methods: About 76 clinically stable patients diagnosed as NCFB were included. Data extraction was done using structured proforma. The BSI and FACED scores were calculated. The serum parameters albumin, CRP (C-reactive protein), ANC (Absolute neutrophil count) and Hb (hemoglobin) levels were estimated. The number of exacerbations and hospitalizations during the 6 months follow up period were recorded.

Results: The mean value of the serum parameters albumin, CRP, absolute neutrophil count (ANC) and Hb were 3.86 (95% CI 3.77- 3.95), 19.61 (95% CI 15.53 -23.68), 8632.95 (95% CI 7258.5-10068) and 12.3 (95% CI 11.84- 12.74) respectively. There was strong negative correlation between serum albumin and the BSI and FACED score. The mean exacerbations and hospitalizations during the 6 months follow up period were 3.3 (95% CI 2.93-3.65) and 1.14 (95% CI 0.85-1.44) respectively.

Conclusions: The serum albumin level exhibited strong correlation and was identified as a variable associated with the BSI and FACED scores. Further studies in this direction are needed for use of serum parameters in severity assessment.



Full Text:



Pasteur MC, Bilton D, Hill AT. British thoracic society guideline for non-CF bronchiectasis. Thorax. 2010;65(1):1-58.

Ringshausen FC, de Roux A, Pletz MW. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends. PLoS One. 2013;8:e71109.

Quint JK, Millett ER, Joshi M. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J. 2016;47:186-93.

Weycker D, Edelsberg JE, Oster G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12:205-9.

Seitz AE, Olivier KN, Adjemian J. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000-2007. Chest. 2012;142:4329.

Wong C, Jayaram L, Karalus N. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660-7.

Roberts ME, Lowndes L, Milne DG, Wong CA. Socioeconomic deprivation, readmissions, mortality and acute exacerbations of bronchiectasis. Intern Med J. 2012;42:e129-e36.

Aliberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J. 2016; 47:1113-22.

Martinez-Garcia MA, Vendrell M, Giron R, Maiz-Carro L, de la Rosa Carrillo D, de Gracia J, et al. The multiple faces of non-cystic fibrosis bronchiectasis: A cluster analysis approach. Ann. Am. Thorac Soc. 2016;13:1468-75.

Saleh AD, Hurst Jr. How to assess the severity of bronchiectasis. Eur Respir J. 2014;43:1217-9.

Lim HY, Abisheganaden JA, Lim AYH. Serum predictors for outcome of hospitalization during exacerbation of bronchiectasis in adults. Am J Resp Critic Care Med. 2015;191:A2446.

Martinez-Garcia MA, de Gracia J, Relat MV. Multidimensional approach to non-cystic fibrosis bronchiectasis the FACED score. Eur Respir J. 2014;43:1357-67.

Chalmers JD, Goeminne P, Aliberti S. The bronchiectasis severity indexes an international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576-85.

McDonnell MJ, Aliberti S, Goeminne PC, Dimakou K, Zucchetti SC, Davidson J, et al. Multidimensional severity assessment in bronchiectasis: An analysis of seven European cohorts. Thorax. 2016;71(12):1110-8.

Saxer S, Gompelmann D, Eberhardt R, Fortin M, Kemp SV, Shah PL, et al. Joint chest-SGP congress 2017. Basel, Switzerland, 7-9 June 2017: Abstracts. Respirat. 2017;94(1):76-156.

Ip M, Lam WK, Chan JC, Liong E. Systemic effects of inflammation in bronchiectasis. Respirat Med. 1991;85(6):521.

Boussoffara L, Boudawara N, Touil I, Khelifa MB, Sakka M, Knani J. Nutritional status in patients with bronchiectasis. European Respirat J. 2012;40:P599.